The prothrombin time (PT) and kaolin partial thromboplastin time (KPTT; also called kaolin cephalin clotting time) tests are widely used as screening procedures for clotting defects. In the diagnosis of isolated, life-long clotting disorders, it is well recognized that both tests will be prolonged by defects of fibrinogen, prothrombin, factor V, and factor X; that a defect of factor VII prolongs only the PT; and that defects of factors VIII, IX, XI or XII prolong only the KPTT. The most satisfactory discrimination between the defects is obtained by testing the ability of the patient's plasma to correct the prolonged clotting times of known, naturally occurring defective plasmas obtained from reference patients, either as qualitative tests or as assays. However, where such plasmas are not available, reagents may be prepared instead from normal plasma. Two alternative principles may be involved: either a concentrate of one or more factors may be added to the patient's plasma in an attempt to correct the defect and thus identify the factor missing from the patient's plasma; or the patient's plasma may be added to reagents with known defects (as in using natural plasmas) to see which are corrected, and thus to identify the components present in the patient's plasma.
The commonest life-long clotting disorders are haemophilia, Christmas disease, and von Willebrand's disease, involving defects of factors VIII or IX. In either defect the PT will be normal but the PTT prolonged; and it has been pointed out that correction of the PTT by the addition of 1 in 5
Received for publication 25 February 1975. Al(OH)3-adsorbed fresh normal plasma suggests a factor-VIII defect whereas correction by an eluate from the Al(OH)3 suggested a factor-IX defect (Knights and Ingram, 1967) . This technical approach has now been extended to cover other clotting factor defects.
Experiments undertaken in developing the method are described, the findings in reference patients are given, and the suggested diagnostic screening procedure is set out as a dichotomous key. and (b) 0-91 g KH2PO4, each in 100 ml water; take 9 7 vol of (a) with 03 vol of (b). More detail is given by Knights and Ingram (1967) .
Aged normal serum was made by allowing normal blood to clot in glass tubes at 37°C, centrifuging after 1 hr and removing the serum which was incubated for a further 6 hr; it may be stored frozen, and diluted 1 in 5 in tris buffer for use. A more standardized product was made by adding an equal volume of 25 mM CaCI2 solution to citrated plasma with 1 % (v/v) brain thromboplastin, mixing, and incubating for 6 hr: the separated serum is diluted 1 in 2 in tris buffer for use.
Celite-adsorbed normal plasma, with factors V and VIII added, was made by the method of Giddings (1971) as an artificial XI-deficient substrate.
Contact product was made as described by Wilson, Ingram, and Hills (1971) and latterly by the modifications given by Perez-Requejo and Ingram (1975) .
Methods
The PT was performed as described by Hardisty and Ingram (1965 In the PT, the specified reagents were added to the patient's and control tubes before the thromboplastin and CaC12 solution. In the KPTT, reagents were added either before or after the 10-min preincubation with kaolin, as specified. The performance of the test may be illustrated from the following modification of the procedure of Knights and Ingram (1967) for adding adsorbed plasma and eluate to the KPTT before incubation with kaolin (table I) .
Into each of six clotting tubes in the water bath at 37°C was placed 0-1 ml kaolin suspension. To the first tube was added 0-1 ml tris buffer and 0-1 ml control plasma; the contents were mixed and a watch was started. One minute later 0-1 ml tris buffer and 01 ml patient's plasma were added to the second The effect of contact product was assessed by performing the PTT on a mixture of 0 1 ml volumes of test or control plasma, phospholipid, CaCl2-solution, and contact product, added in succession in that order. Before use, the contact product was diluted so that the clotting time obtained from the control plasma in the PTT with contact product was the same as that obtained on the same plasma in the KPTT, to make it possible to compare the patient-control differences in the two tests.
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The contact activation test was modified from Margolis (1957) , after Hardisty and Ingram (1965) , by exposing samples of the patient's or control plasma to Celite 512 and observing the degree of shortening afforded by these plasmas when added in various dilutions to uncontacted normal plasma. In the Celite-6 test for factor XI, quoted by Hardisty and Ingram (1965) , normal plasma was depleted of factor XI by prior incubation with Celite 512; and mixtures of the control of patient's plasmas with this plasma were tested for their ability to shorten the clotting time of intact normal plasma. Since several dilutions were tested in both procedures, it was possible to calculate from the results the activity of the patient's plasma as a ratio to that of the control plasma as a parallel-line bioassay.
Patients
Patient B, male (factor-XI deficiency) aged 38, had been detected in routine testing before intended haemorrhoidectomy. He had previously suffered excessive bleeding after an operation for hernia and after an injury in a road traffic accident. He gave no history of haemarthrosis and did not suffer from abnormal spontaneous bleeding. The original diagnosis had been made by Dr P. Aggler; he was subsequently investigated at the Haemophilia Centre at Oxford where his KPTT was 147 s but was completely corrected by the addition of contact product: no factor XI-activity could be detected.
Patient H, male (factor-XI deficiency) aged 46, had bled for two to three days after dental extractions aged 30 and 37, although he had survived tonsillectomy in childhood and did not recall prolonged postoperative bleeding. His factor-XI activity assayed in Giddings' system was < 1 % of control; but the contact activation and Celite-6 tests gave activities of 17 and 21 % respectively; whatever may explain the discrepancy between the results in these tests and in Giddings' reagent, the agreement between the results in the two simpler systems supports the conclusion that H's contact defect is explained by his deficiency of factor XI.
Patient P, male (factor-VIII deficiency) aged 30, is a severely affectedhaemophiliac who has frequently attended this Haemophilia Centre during the last 15 years and was previously treated at The Hospital for Sick Children, Great Ormond Street, London. His blood shows no factor-VILL activity; he does not have an antibody to factor VIII. His plasma has often been used as the basis for factor-VIII assays.
Patient R, female (factor-XII deficiency) aged 38, had not bled abnormally after an operation for perforated duodenal ulcer aged 14 nor after a nasal plastic repair operation in adult life. She did not appear to bruise unduly easily but had suffered from troublesome epistaxes until recently. Her platelet count, bleeding time, and prothrombin time were normal but the whole-blood clotting time and kaolin partial thromboplastin time were prolonged. Using a modification of the latter test on the mixtures of the patient's plasma and various reference plasmas, the patient's plasma had been shown at the Oxford Haemophilia Centre to be grossly deficient in factor XII. On thepresent occasion the whole-blood clotting time was ca 23 min in glass tubes and ca 45 min in silicone-coated tubes.
Patient S, female (factor-XII deficiency) aged 28, was a blood donor whosedeficiencyhad been detected through the delayed clotting of a blood sample; it was later learned that bleeding had been excessive after tonsillectomy and after dental extraction, but transfusion had not be.n required (Marsh and Jenkins, 1961 degree of correction shown in the plasmas of B and S is the general rule with XI-deficient and XIIdeficient plasmas respectively. Table IV shows the effect of adding contact product to the partial thromboplastin time tests on plasma samples from B and R (both factor XII-deficient) by comparison with the effect of pre-incubation with kaolin. It is seen that contact product completely corrects the defect in both cases. For comparison, the three plasmas of table III were similarly tested: on the addition of contact product to patients' and control plasmas, in place of kaolin preincubation and addition of AI(OH)3-plasmas, the patient minus control differences for the three plasmas were: P (factor-VIII-deficient), 82-0 s: B (factor-XI-deficient), 40 s; and S (factor-XII-deficient), 6-7 s. Thereis thus a clear differentiation between haemophilia and the contact factor defects; and the correction of the contact-factor-defective plasmas ' Tests contained in addition a vol of tris buffer Factors XI and XII were both assayed but only the lower value is tabulated. These cases were identified in the course of routine work by the screening procedure using contact product. The test was applied because the KPTT difference was greater than the critical value of 6 s (Matchett and Ingram, 1965) ; note that the difference between the KPTT and contact product PTT differences was also greater than 6 s. Case I is obviously doubtful, with 72 % factor XI (factor XII, 82 %), but no other abnormality could be found and there was a clear history of a number of occurrences of abnormal post-traumatic bleeding. Only case 2 was asymptomatic; he was tested because he was the brother of case 3. The other cases are all from separate families. In general, there is a relationship between the magnitude of the difference in col 6 and the degree of abnormality in cols 7 or 8. (Knights and Ingram, 1967) Contact product (P6rez-Requejo and Ingram, 1975) Celite-adsorbed normal plasma (factor XI-deficient) with factors V and VIII added (Giddings, 1971) Thrombin solution, ca 5 NIH u/ml Immunological test for fibrinogen Note that the key may fail if the defect is not sufficiently marked to prolong the patient's PT by at least 10 s or the patient's KPTT by at least 15 s over the control; if more than one clotting factor is defective; or in the presence of a clotting inhibitor or an inactivator of a clotting factor, both of which must first be excluded by the mixing tests described.
When the initial difference between the patient's and control clotting times is very long, suggesting a major abnormality, the presence of an inactivator of a clotting factor (for example, an anti-factor-VIII antibody) should be sought by incubating equal volumes of the patient's and the control plasmas in sufficient quantity to withdraw aliquots periodically (say, over 2 hr) and repeat whichever test initially demonstrated the abnormality. Control readings are obtained by incubating in parallel separate samples of the patient's and the control plasmas, and testing freshly made 50:50 mixtures from them in parallel with the tests on the incubated mixture (Hardisty and Ingram, 1965 It has therefore been assumed that such reagents will be available if necessary.
